58
Participants
Start Date
January 31, 2014
Primary Completion Date
January 31, 2019
Study Completion Date
November 30, 2020
Rituximab
i.v. rituximab given on two occasions 14 days apart.
Placebo
Subjects randomized to placebo will receive two i.v. doses of 5% dextrose in water (D5W) in the same schedule as the rituximab subjects. The D5W and rituximab preparations will be indistinguishable.
University of Pittsburgh Medical Center, Pittsburgh
Geisinger Medical Center, Danville
Temple University, Philadelphia
Medical University of South Carolina, Charleston
University of Alabama at Birmingham, Birmingham
University of Minnestoa, Minneapolis
Brigham and Women's Hospital, Boston
National Institutes of Health (NIH)
NIH
University of Alabama at Birmingham
OTHER